NCT00981721View on ClinicalTrials.gov

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

April 30, 2011

Conditions
Advanced Solid Malignancies
Interventions
DRUG

cediranib (RECENTIN TM, AZD2171)

20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8

Trial Locations (2)

Unknown

Research Site, Beijing

Research Site, Hong Kong

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00981721 - A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter